文献速递乳腺癌骨软组织肉瘤与黑色素瘤

致病或可能致病性胚系TP53变异携带者的癌症发病率、模式及基因型-表型关联:一项观察性队列研究

Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
PubMed 文献 · Lancet Oncol · 2021-11-12

该观察性队列研究纳入480例致病或可能致病性胚系TP53变异携带者,比较其与普通人群的癌症发病率。携带者任何癌症的标化发病比为23.9(95%CI 21.9-26.0),50岁后仍为10.3(95%CI 7.9-13.2)。DNE_LOF和notDNE_LOF变异与更早的首发和第二次癌症年龄相关。

要点

  • 李-佛美尼综合征患者任何癌症发病率约为普通人群的24倍,50岁后仍约10倍。
  • 女性至33.7岁时,非乳腺癌恶性肿瘤首次诊断概率为24.4%,低于任何癌症的50.4%。
  • DNE_LOF和notDNE_LOF变异携带者首次和第二次癌症年龄更早。

核心结论

  • 本研究细化了致病或可能致病性胚系TP53变异携带者的癌症发病率和模式。
  • 整合年龄范围特异性癌症发病率估计、按功能变异组的无癌生存、降低风险乳房切除术对女性癌症发病率的潜在影响及后续恶性肿瘤数据,对优化筛查和管理策略很重要。

研究设计与样本

  • 观察性队列研究,纳入2011年8月1日至2020年3月24日在美国国家癌症研究所转诊为基础的纵向李-佛美尼综合征研究中入组的480例致病或可能致病性胚系TP53变异携带者。
  • 通过研究问卷获取个人和家族癌症史,并经医疗记录验证。
  • 变异按功能丧失(LOF)和显性负效应(DNE)特性分类。
  • 癌症发病率与SEER 1975-2017登记处的普通人群比较,采用家族聚类Cox回归模型和竞争风险方法。
  • 研究注册于ClinicalTrials.gov,NCT01443468。

主要发现

  • 李-佛美尼综合征患者任何癌症的标化发病比为23.9(95%CI 21.9-26.0),儿童至30岁比较发病率最高。
  • 50岁后总体癌症发病率仍为普通人群的10.3倍(95%CI 7.9-13.2)。
  • 女性至33.7岁时,考虑乳腺癌为竞争风险,非乳腺癌恶性肿瘤首次诊断概率为24.4%(95%CI 19.6-30.5),任何癌症首次诊断概率为50.4%(95%CI 43.5-56.5)。
  • DNE_LOF和notDNE_LOF变异与notDNE_notLOF和DNE_notLOF变异相比,与更早的首发和第二次癌症年龄相关。
  • 首次至第二次癌症的时间间隔在首次癌症诊断较晚的携带者中更短,部分个体在短时间内诊断多种癌症,与癌症发生顺序无关。

关键数值与推荐

  • 任何癌症标化发病比23.9(95%CI 21.9-26.0)。
  • 50岁后癌症标化发病比10.3(95%CI 7.9-13.2)。
  • 女性至33.7岁时非乳腺癌恶性肿瘤首次诊断概率24.4%(95%CI 19.6-30.5),任何癌症50.4%(95%CI 43.5-56.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Li-Fraumeni syndrome, caused primarily by pathogenic or likely pathogenic germline TP53 variants, is a rare, variably penetrant, cancer predisposition syndrome with very high risks of cancer starting in childhood, including the risk of multiple primary malignancies over an individual's lifespan. We aimed to characterise and quantify cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants. METHODS: This observational cohort study was done in 480 carriers of pathogenic or likely pathogenic germline TP53 variants enrolled in the National Cancer Institute's referral-based longitudinal Li-Fraumeni syndrome study between Aug 1, 2011, and March 24, 2020. Data on personal and family history of cancer were obtained through study questionnaires and validated by medical records. Variants were categorised on the basis of both loss-of-function (LOF) and dominant-negative effect (DNE) properties. Cancer incidence associated with Li-Fraumeni syndrome was compared with that of the general population using the Surveillance, Epidemiology, and End Results (SEER) 1975-2017 registry. Cancer incidence was evaluated with family-clustered Cox regression models and competing risk methods. This study is registered with ClinicalTrials.gov, NCT01443468. FINDINGS: Individuals with Li-Fraumeni syndrome had a nearly 24 times higher incidence of any cancer than the general population (standardised incidence ratio 23·9; 95% CI 21·9-26·0), with the highest comparative incidence from childhood to 30 years of age. The overall cancer incidence remained 10·3 (95% CI 7·9-13·2) times higher than that of the general population after age 50 years. In women, when considering breast cancer as a competing risk, the probability of a first diagnosis of a non-breast cancer malignancy was substantially lower than that of any first cancer (24·4% [95% CI 19·6-30·5] vs 50·4% [43·5-56·5] by age 33·7 years). Overall, DNE_LOF and notDNE_LOF variants were associated with earlier age at first and second cancer compared with notDNE_notLOF and DNE_notLOF variants. The time interval from first to second cancer was shorter among carriers whose first cancer diagnoses were later in life. Multiple cancers were diagnosed within a short timeframe in some individuals, regardless of the order of cancer occurrence. INTERPRETATION: This study adds granularity to the understanding of cancer incidence and patterns in individuals with pathogenic or likely pathogenic germline TP53 variants. Integration of age range-specific cancer incidence estimates, cancer-free survival by functional variant group, the potential impact of risk-reducing mastectomy on female cancer incidence, and data on subsequent malignancies will be important for the development of strategies to optimise cancer screening and management for these individuals. FUNDING: Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. de Andrade KC, Khincha PP, Hatton JN, et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021. PMID: 34780712. doi:10.1016/S1470-2045(21)00580-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。